Wednesday, September 18, 2023

Program subject to change.

7:15 am - 8:15 am | Concurrent Industry-Sponsored Symposia

Frontage Laboratories Industry-Sponsored Symposium: A Hybrid Trial Approach by Combining 13C8-Labeled and Radiolabeled Brilaroxazine to Assess Absolute Bioavailability and hAME in A Single Clinical Trial
Li Shen, Drug Metabolism and Pharmacokinetics of Frontage Laboratories, Exton, Pennsylvania, USA

Thermo Fisher Scientific Industry-Sponsored Symposium: Engineering Patient-Derived Tumoroids to Enable High-Throughput Screening for Immuno-Oncology Research
Kevin J. Pridham, Thermo Fisher Scientific, Carlsbad, California, USA

8:30 am - 9:30 am | Plenary Lecture 2

Species Specificity and Selection of Animal Models for Drug Oxygenations Differently Contributed by Polymorphic Human Enzymes

Hiroshi Yamazaki, Showa Pharmaceutical University, Machida, Japan

9:30 am - 10:00 am | Break with Posters and Exhibitors

9:45 am - 10:00 am | SCIEX Thought Leadership Presentation: MetID Innovations : Unveiling New Paths for Revealing Metabolite Structures
Ming Yao, BMS

10:00 am - 12:00 pm | Concurrent Symposia 7 and 8

Symposium 7: Solving ADME/Tox Challenges in Drug Discovery
Co-Chairs: Hideki Hirabayashi, Takeda, Japan and Deepak Dalvie, Crinetics, San Diego, California, USA

Discovery of PF-07817883, a Second-Generation Oral SARS-CoV2 Main Protease Inhibitor
Amit Kalgutkar, Pfizer, Cambridge, Massachusetts, USA

Uncovering Target-Mediated Drug Disposition (TMDD) of Small Molecule Brain Penetrant EBP Inhibitors
Laurent Salphati, Genentech, South San Francisco, California, USA

A Tale of Preclinical Insights into Bile Salt Homeostasis Disruption in DILI
Yurong Lai, Gilead, Dublin, California, USA

Best Practice of Mitigating P-glycoprotein Liabilities in Drug Discovery - Assessment and Prediction of P-gp Mediated Nonlinear PK, Brain Penetration, and Interactions
Hideki Hirabayashi, Takeda, Fujisawa, Japan

Symposium 8: Manage Drug Disposition and Toxicity in Specific Population: From Mechanistic Understanding to PBPK Modelling
Co-Chairs: Masayo Oishi, Astellas, Tsukuba-shi, Japan and Xiaoyan Chu, Merck, Rahway, New Jersey, USA

Unraveling Cannabinoids-drug Interactions in Aging: Insights from PBPK Modeling
Zhu Zhou, City University of New York, Jamaica, New York, USA

Model-based Meta-analysis of Ethnic Differences - General Changes in Clearance by Pathways and Aging
Akihiro Hisaka, Chiba University, Chiba, Japan

Mechanisms Underlying Altered Drug Clearance in Pregnancy
Muluneh Fashe, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA

Alteration of Blood Brain-barrier Proteome in Various Conditions
Sumio Ohtsuki, Kumamoto University, Kumamoto, Japan

12:00 pm - 2:30 pm | Exhibits, Poster Presentations, and Thought Leadership Presentations

12:00 pm -12:30 pm | Lunch on Own, Exhibit Hall Hours, and Poster Viewing

12:30 pm - 2:30 pm: Poster Presentation Session 3 - P215 - P338 and P342

12:30 pm - 1:30 pm | Odd-numbered Poster Presentation Session

1:30 pm - 2:30 pm | Even-numbered Poster Presentation Session

12:45 pm - 1:00 pm | Charles River Thought Leadership Presentation: Challenges and Opportunities for Improved Prediction of CNS Penetration Across Species
Zusuzsanna Gaborik, Charles River

1:20 pm - 1:35 pm | Frontage Thought Leadership Presentation: Strategies for Conducting Preclinical and Clinical Studies with Radiolabeled Compounds – Why, When, and Where
Koppara Samuel, M.S., M.Sc., Frontage

1:45 pm - 2:00 pm | Ellegaard Bioresearch Thought Leadership Presentation: Göttingen Minipigs as an Alternative Non-rodent Animal Model in Drug Development
John Cameron, M.S., Regional Business Development Director North America, Ellegaard Bioresearch

2:30 pm - 4:30 pm | Plenary Session

Digging Into the Complexities of Natural Products with Integrative Tools to Improve Pharmacotherapy
Co-Chairs: Mary Paine, Washington State University, Spokane Washington, USA and Huichang (Nancy) Bi, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China

Authenticity and Adulteration of Botanical Natural Products: Lessons from a Decade of Sourcing Materials for Scientific Investigation
Nadja Cech, University of North Carolina Greensboro, Greensboro, North Carolina, USA

Schisandra Sphenanthera: Its Hepatoprotection and Beyond
Huichang Bi, Southern Medical University, Guangzhou, China

Botanical-Drug Interactions: Blazing the Trail Using Translational Tools
Mary Paine, College of Pharmacy & Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA

Challenges and Breakthroughs in the Conduct of Clinical Cannabis Studies
Ryan Vandrey, Johns Hopkins University, Baltimore, Maryland, USA

Developing Natural Products as Potential Therapeutic Agents
Amala Soumyanath, Oregon Health & Science University, Portland, Oregon, USA